Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Keith Ignotz
AddedFeb 15, 2024
UpdatedMay 31, 2026
Keith Ignotz

Keith Ignotz

Co-Founder, Guided Therapeutics

CrunchbaseLinkedInThe Org

Keith Ignotz's Career

Guided Therapeutics
Guided Therapeutics

Peachtree Corners, GA, US

Co-Founder
OcuMedic
OcuMedic

Mullica Hill, NJ, US

CEO· C-Suite · Management
Freedom Meditech
Freedom Meditech

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Keith Ignotz's Career

Guided Therapeutics
Guided Therapeutics

Peachtree Corners, GA, US

Co-Founder
OcuMedic
OcuMedic
Series A$250k72006Mullica Hill, NJ, US
CEO· C-Suite · Management

Leadership at OcuMedic

Mark ByrneMark ByrneBoard Member
Paul ByrnePaul ByrneFounder

Similar to OcuMedic

OcuCure TherapeuticsOcuCure TherapeuticsRoanoke, VA, USEye Drops, Pharmaceuticalsest. 2005OcuCure TherapeuticsRoanoke, VA, US · est. 2005

OcuCure Therapeutics: Developing innovative eye drops for age-related and diabetic eye diseases since 2005.

Public · $3.3M8
MediPrint OphthalmicsMediPrint OphthalmicsSan Diego, CA, USPharmaceuticalsest. 2001MediPrint OphthalmicsSan Diego, CA, US · est. 2001

San Diego-based MediPrint Ophthalmics develops and commercializes proprietary ocular drugs to protect sight.

Series A · $7M7
Freedom Meditech
Freedom Meditech
Series C$19.6M302006San Diego, CA, US
Board Member· Board

Leadership at Freedom Meditech

John BurdJohn BurdBoard Member
Craig MisrachCraig MisrachFounder
Andrew SassineAndrew SassineBoard Member
Mr. Craig H. MisrachMr. Craig H. MisrachBoard Member

Similar to Freedom Meditech

Free Flow MedicalFree Flow MedicalFremont, CA, USMedical Devicesest. 2017Free Flow MedicalFremont, CA, US · est. 2017

Free Flow Medical: Innovating next-gen devices for emphysema treatment to enhance patient life quality.

Series B · $4.9M30
Bioxytech RetinaBioxytech RetinaRichmond, CA, USMedical Devicesest. 2015Bioxytech RetinaRichmond, CA, US · est. 2015

Bioxytech Retina, founded in 2015, pioneers non-invasive optical devices for diabetes diagnosis.

Pre-Seed · $1.2M5
Channel MedsystemsChannel MedsystemsSan Francisco, CA, USMedical Devicesest. 2009Channel MedsystemsSan Francisco, CA, US · est. 2009

San Francisco-based Channel Medsystems develops and delivers non-invasive medical technology products.

Series A · $62.9M35
Noninvasive Medical TechnologiesNoninvasive Medical TechnologiesLas Vegas, NV, USMedical Devicesest. 2006Noninvasive Medical TechnologiesLas Vegas, NV, US · est. 2006

NMT: Innovating noninvasive hemodynamic monitoring tools for enhanced medical care since 2003.

Series A · $6.3M11

Keith Ignotz's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Keith Ignotz

Paul GrandPaul GrandFounder · Medtech InnovatorThomas WenchellThomas WenchellCo-Founder · RevmedicaMichelle O'ConnorMichelle O'ConnorCEO · MeditechAlan LucasAlan LucasFounder & CEO · Navigation SciencesDenis KhitrovDenis KhitrovCo-Founder · MedM